文献速递性腺与生殖内分泌

睾酮替代治疗与老年性腺功能减退男性前列腺疾病风险的关联

Association Between Testosterone Replacement Therapy and Prostatic Disorders in Elderly Hypogonadal Men.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

这项大型回顾性队列研究分析2007至2020年Medicare数据,纳入65岁以上原发性或继发性性腺功能减退男性,采用Cox回归和1:1倾向评分匹配评估睾酮替代治疗(TRT)与前列腺结局的关联。结果显示TRT使用与前列腺癌风险降低16%相关(HR=0.84;95%CI:0.82-0.86),与良性前列腺增生风险增加13%相关(HR=1.13;95%CI:1.11-1.14),且关联因治疗时长、给药途径和芳香化酶抑制剂合用而异。

要点

  • TRT使用与前列腺癌风险降低16%相关(HR=0.84;95%CI:0.82-0.86)。
  • TRT使用与良性前列腺增生风险增加13%相关(HR=1.13;95%CI:1.11-1.14)。
  • 关联因治疗时长、给药途径和芳香化酶抑制剂合用而异。

核心结论

  • TRT使用与前列腺癌风险降低及良性前列腺增生风险轻度增加相关。
  • 这些关联因治疗时长、给药途径和芳香化酶抑制剂合用而异。
  • 研究结果可能为性腺功能减退男性TRT临床决策提供参考并支持个体化诊疗。

研究设计与样本

  • 大型回顾性队列研究,分析2007至2020年Medicare参保与索赔数据(Parts A/B/C/D)。
  • 纳入65岁以上确诊原发性或继发性性腺功能减退的男性。
  • 采用Cox回归分析和1:1倾向评分匹配,并按年龄组分层。
  • TRT使用按治疗时长、给药途径和芳香化酶抑制剂合用分类。

主要发现

  • 倾向评分匹配后,前列腺癌风险分析纳入546 964例,良性前列腺增生风险分析纳入412 782例性腺功能减退男性。
  • TRT使用与前列腺癌风险降低16%相关(HR=0.84;95%CI:0.82-0.86),长期使用降低15%,短期使用降低16%,肠外给药降低12%,局部给药降低13%。
  • 排除前列腺特异性抗原升高和有前列腺癌家族史者的敏感性分析显示,TRT使用者前列腺癌风险降低18%。
  • TRT使用与良性前列腺增生风险增加13%相关(HR=1.13;95%CI:1.11-1.14),肠外给药增加19%,局部给药增加12%,长期局部使用增加9%。

临床怎么用

  • 临床决策时可参考TRT与前列腺癌风险降低及良性前列腺增生风险轻度增加的关联。
  • 考虑TRT时需结合治疗时长、给药途径和芳香化酶抑制剂合用进行个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Concerns about potential prostate-related complications associated with testosterone replacement therapy (TRT) often lead hypogonadal men to remain untreated. METHODS: This large-scale retrospective cohort study aimed to address these concerns by analyzing Medicare enrollment and claims data (Parts A/B/C/D) from 2007 to 2020 for men aged ≥65 with diagnosed primary or secondary hypogonadism. Cox regression analysis and 1:1 propensity score matching, both stratified by age group, were employed to evaluate the association between prostate outcomes and TRT use. TRT use was further categorized by treatment duration, administration route, and aromatase inhibitor (AI) coadministration. RESULTS: Following propensity score matching, the prostate cancer (PCa) and benign prostatic hyperplasia (BPH) risk analyses included 546 964 and 412 782 hypogonadal men, respectively, with comparable baseline characteristics at the time of hypogonadism diagnosis. TRT use was linked to a significant 16% reduction in the hazard of PCa (HR = 0.84; 95% CI: 0.82-0.86), including reductions observed across long-term (15%), short-term (16%), parenteral (12%), and topical (13%) use. Sensitivity analyses excluding individuals with elevated prostate-specific antigen and family history of PCa similarly demonstrated a 18% reduction in the hazard of PCa among TRT users. Conversely, TRT use exhibited a 13% increase in the hazard of BPH (HR = 1.13; 95% CI: 1.11-1.14), with a larger increase for parenteral (19%) vs topical TRT (12%). Notably, long-term topical use was linked to a modest 9% increase. CONCLUSION: TRT use was associated with reduction in PCa hazard and modest increase in BPH hazard. These associations varied by treatment duration, route, and AI coadministration. These findings may inform clinical decision-making regarding TRT use in hypogonadal men and support a more individualized approach to care.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Baik SH, Baye F, Fung KW, et al. Association Between Testosterone Replacement Therapy and Prostatic Disorders in Elderly Hypogonadal Men. J Clin Endocrinol Metab. 2026. PMID: 40922669. doi:10.1210/clinem/dgaf504

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。